论文部分内容阅读
[目的]观察吉西他滨联合奥沙利铂治疗晚期肝内胆管细胞癌临床效果及毒副作用。[方法]28例肝内胆管细胞癌患者均给予吉西他滨1000mg/m2,d1、8;奥沙利铂85mg/m2,d1,21d为1个疗程。观察近期疗效、疼痛缓解程度和毒副反应。[结果]化疗后PR6例(21.43%),SD12例(42.86%),PD10例(35.71%),化疗期间无死亡病例。疼痛程度化疗前后比较差异有统计学意义(P<0.05)。毒副作用以血液系统多见,其次为胃肠道反应和外周神经毒性。[结论]吉西他滨联合奥沙利铂治疗晚期肝内胆管细胞癌具有较好的近期疗效,能缓解患者疼痛,且毒副反应可以耐受。
[Objective] To observe the clinical effect and side effects of gemcitabine plus oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma. [Methods] 28 patients with intrahepatic cholangiocarcinoma were given gemcitabine 1000mg / m2, d1,8; oxaliplatin 85mg / m2, d1, 21d for a course of treatment. To observe the short-term efficacy, pain relief and toxicity. [Results] After chemotherapy, there were 6 cases (21.43%) of PR, 12 cases of SD (42.86%) and 10 cases of PD (35.71%). There were no deaths during chemotherapy. The degree of pain before and after chemotherapy was significantly different (P <0.05). Toxic side effects are more common in the blood system, followed by gastrointestinal reactions and peripheral neurotoxicity. [Conclusion] The combination of gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma has good curative effect in the short term, which can relieve the pain of patients and the side effects can be tolerated.